KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Esperion Therapeutics (ESPR) Return on Sales (2019 - 2026)

Esperion Therapeutics filings provide 7 years of Return on Sales readings, the most recent being 0.0% for Q4 2025.

  • On a quarterly basis, Return on Sales rose 1.0% to 0.0% in Q4 2025 year-over-year; TTM through Dec 2025 was 0.0%, a 0.0% change, with the full-year FY2025 number at 0.0%, changed 0.0% from a year prior.
  • Return on Sales hit 0.0% in Q4 2025 for Esperion Therapeutics, up from 0.0% in the prior quarter.
  • In the past five years, Return on Sales ranged from a high of 0.0% in Q1 2024 to a low of 0.11% in Q1 2021.
  • Median Return on Sales over the past 5 years was 0.02% (2023), compared with a mean of 0.02%.
  • The widest YoY moves for Return on Sales: up 31bps in 2021, down -2bps in 2021.
  • Esperion Therapeutics' Return on Sales stood at 0.04% in 2021, then skyrocketed by 33bps to 0.03% in 2022, then soared by 41bps to 0.02% in 2023, then skyrocketed by 76bps to 0.0% in 2024, then surged by 188bps to 0.0% in 2025.
  • The last three reported values for Return on Sales were 0.0% (Q4 2025), 0.0% (Q3 2025), and 0.0% (Q2 2025) per Business Quant data.